Literature DB >> 12171895

Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.

Rosana B Michel1, Rita Ochakovskaya, M Jules Mattes.   

Abstract

Antibody (Ab) localization to Raji B-cell lymphoma xenografts in severe combined immunodeficient (SCID) mice was investigated using three Abs: anti-CD20; anti-CD147; and anti-MHC class II. These antigens are all high-density cell surface antigens, and the Abs are all considered to be slowly internalized and catabolized, with catabolism primarily due to the basal turnover rate of cell surface constituents. Unexpectedly, specific Ab uptake was demonstrated only when residualizing labels were used. The residualizing labels tested were 111In-benzyl-diethylenetriaminepentaacetic acid and [125I]iodo-dilactitol-tyramine, whereas the nonresidualizing label was a conventional iodine label. In contrast, in vitro experiments demonstrated very slow catabolism of the same Abs. These data strongly suggest that Ab catabolism is much more rapid in vivo than in vitro and has a strong impact on Ab accumulation in the tumor. If autologous human tumors are similar to these xenografts, then there should be a large advantage in the use of residualizing radiolabels for radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171895

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

Authors:  Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

2.  Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity.

Authors:  Magdalena Winiarska; Dominika Nowis; Jacek Bil; Eliza Glodkowska-Mrowka; Angelika Muchowicz; Malgorzata Wanczyk; Kamil Bojarczuk; Michal Dwojak; Malgorzata Firczuk; Ewa Wilczek; Malgorzata Wachowska; Katarzyna Roszczenko; Marta Miaczynska; Justyna Chlebowska; Grzegorz Wladyslaw Basak; Jakub Golab
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

Review 3.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

4.  Factors determining antibody distribution in tumors.

Authors:  Greg M Thurber; Michael M Schmidt; K Dane Wittrup
Journal:  Trends Pharmacol Sci       Date:  2008-01-07       Impact factor: 14.819

Review 5.  Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Authors:  Greg M Thurber; Michael M Schmidt; K Dane Wittrup
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

6.  Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons.

Authors:  M Jules Mattes; David M Goldenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

7.  Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells.

Authors:  Rod Balhorn; Saphon Hok; Sally DeNardo; Arutselvan Natarajan; Gary Mirick; Michele Corzett; Gerald Denardo
Journal:  Mol Cancer       Date:  2009-04-22       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.